Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1570 studies found for:    EGFR
Show Display Options
Rank Status Study
21 Completed Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors
Conditions: Metastatic Colorectal Cancer;   Non-Small-Cell Lung Carcinoma
Intervention: Drug: Diprosone
22 Completed Retrospective Study in a NSCLC M+ p
Condition: EGFR Mutated Non-small Cell Lung Cancer Patients
Intervention:
23 Active, not recruiting A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).
Condition: Non Small Cell Lung Cancer
Intervention:
24 Recruiting A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib and Erlotinib, in Non-small Cell Lung Cancer(NSCLC)Treatment
Conditions: Non-small Cell Lung Cancer (NSCLC);;   EGFR-TKI Resistant Mutation;;   EGFR-TKI Sensitizing Mutation;;   Germline Mutations
Intervention:
25 Enrolling by invitation Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC
Condition: Lung Neoplasms
Intervention:
26 Recruiting Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc
Condition: Advanced Stage Non Small Cell Lung Cancer
Interventions: Drug: Erlotinib 100mg qd;   Drug: Gefitinib 250mg qd
27 Completed
Has Results
Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors
Condition: Skin Toxicities
Intervention: Other: Questionnaire
28 Completed A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology
Condition: Non-Small Cell Lung Cancer
Intervention:
29 Unknown  First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene
Conditions: Lung Neoplasms;   Non-Small Cell Lung Cancer;   Adenocarcinoma, Bronchiolo-Alveolar
Intervention: Drug: Erlotinib
30 Recruiting Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer;   Positive EGFR Mutation
Intervention: Drug: BIBW 2992
31 Recruiting Erlotinib 100mg or 150mg in Treating EGFR Mutation NSCLC Patients
Conditions: NSCLC;   Egfr Mutation
Intervention: Drug: Erlotinib
32 Terminated Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells
Condition: Neoplasms, Breast
Intervention: Drug: LAPATINIB
33 Completed Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m
Condition: Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer
Intervention:
34 Active, not recruiting
Has Results
Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Condition: Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Intervention: Drug: Gefitinib
35 Not yet recruiting Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study
Condition: EGFR Mutation Positive Non Small Cell Lung Cancer
Intervention:
36 Active, not recruiting A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR
Condition: NSCLC Patients With EGFR Activating Mutation Who Responded to Erlotinib in the First Line Treatment and Developed an Acquired Resistance.
Interventions: Drug: ERLOTINIB WITH CHEMOTHERAPY;   Drug: CHEMOTHERAPY ONLY
37 Completed Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions
Condition: Advanced Colorectal Cancer
Intervention: Drug: Cetuximab, irinotecan
38 Completed Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer
Condition: Non-Small-Cell Lung Carcinoma
Intervention:
39 Recruiting A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
Conditions: Lung Cancer;   Non-Small Cell Lung Cancer
Interventions: Drug: MEK162;   Drug: Erlotinib
40 Recruiting A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status
Condition: NSCLC
Intervention: Other: EGFR mutation status in patients

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years